Skip to main content
ImmuneCited

Pediatric vitiligo.

Nanette B Silverberg
Review Pediatric clinics of North America 2014 25 citas
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D24636650'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo de estudio
Review
Población
Children with vitiligo
Intervención
Pediatric vitiligo. None
Comparador
None
Resultado primario
Pediatric vitiligo management
Dirección del efecto
Positive
Riesgo de sesgo
Unclear

Abstract

Vitiligo is a disease of pigment loss. Most investigators currently consider vitiligo to be a disorder that occurs as a result of autoimmune destruction of melanocytes, supported by identification of antimelanocyte antibodies in many patients, and the presence of comorbid autoimmune disease in patients with and family members of individuals with vitiligo. One-half of vitiligo cases are of childhood onset. This article presents a current overview of pediatric vitiligo including comorbidities of general health, psychological factors, therapeutic options, and long-term health considerations.

TL;DR

A current overview of pediatric vitiligo including comorbidities of general health, psychological factors, therapeutic options, and long-term health considerations is presented.

Used In Evidence Reviews

Similar Papers